“…BIT225 showed no antiviral activity…”, page-2

Good post shareman and questions need to be asked. But will they answer them? I think not. My concern with BIT is that if their/our compounds have commercial applications, why is it that no large Pharmas have taken a stake in BIT. Either as a future partner for commercialization, or even as a blocking stake. Given the size of the HIV market and the MC of BIT it would seem a no brainer. They could probably buy BIT for 50c a share which is still sub 400 mill. Plus, we have the CV compounds, or do we? No news is suss to me..All IMO...